News articles about Celgene Corporation (NASDAQ:CELG) have been trending somewhat positive this week, Accern Sentiment reports. Accern rates the sentiment of media coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Celgene Corporation earned a media sentiment score of 0.23 on Accern’s scale. Accern also assigned news articles about the biopharmaceutical company an impact score of 87 out of 100, indicating that recent media coverage is very likely to have an impact on the stock’s share price in the immediate future.

Here are some of the news articles that may have effected Accern Sentiment’s analysis:

Celgene Corporation (NASDAQ CELG) traded up 0.26% during midday trading on Monday, hitting $137.06. 2,874,377 shares of the company traded hands. The stock has a 50 day moving average price of $132.00 and a 200-day moving average price of $123.32. Celgene Corporation has a 12-month low of $96.93 and a 12-month high of $139.00. The company has a market cap of $107.23 billion, a PE ratio of 42.45 and a beta of 1.89.

Celgene Corporation (NASDAQ:CELG) last posted its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.82 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.61 by $0.21. The firm had revenue of $3.27 billion during the quarter, compared to the consensus estimate of $3.23 billion. Celgene Corporation had a return on equity of 68.51% and a net margin of 21.35%. The business’s revenue was up 18.7% compared to the same quarter last year. During the same period last year, the company earned $1.44 earnings per share. Analysts expect that Celgene Corporation will post $7.32 EPS for the current year.

A number of brokerages have commented on CELG. Mizuho set a $134.00 target price on shares of Celgene Corporation and gave the stock a “buy” rating in a research note on Wednesday, July 26th. Cantor Fitzgerald set a $160.00 price target on shares of Celgene Corporation and gave the stock a “buy” rating in a report on Thursday, July 27th. Robert W. Baird reiterated an “outperform” rating and set a $162.00 price target on shares of Celgene Corporation in a report on Friday, July 21st. Jefferies Group LLC reiterated a “buy” rating and set a $160.00 price target on shares of Celgene Corporation in a report on Monday, July 31st. Finally, Cann reiterated a “buy” rating and set a $175.00 price target on shares of Celgene Corporation in a report on Tuesday, August 1st. One analyst has rated the stock with a sell rating, six have assigned a hold rating and twenty-three have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $147.06.

COPYRIGHT VIOLATION WARNING: This article was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this article on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright laws. The correct version of this article can be viewed at https://www.thecerbatgem.com/2017/08/08/celgene-corporation-celg-getting-somewhat-favorable-press-coverage-study-shows-updated-updated-updated.html.

In other news, Director Gilla Kaplan sold 7,500 shares of Celgene Corporation stock in a transaction that occurred on Wednesday, August 2nd. The stock was sold at an average price of $134.52, for a total transaction of $1,008,900.00. Following the completion of the transaction, the director now directly owns 76,301 shares in the company, valued at approximately $10,264,010.52. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Rupert Vessey sold 4,785 shares of Celgene Corporation stock in a transaction that occurred on Thursday, June 15th. The stock was sold at an average price of $120.18, for a total value of $575,061.30. Following the transaction, the insider now owns 4,004 shares of the company’s stock, valued at $481,200.72. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 235,255 shares of company stock valued at $31,377,042. Corporate insiders own 0.95% of the company’s stock.

Celgene Corporation Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Insider Buying and Selling by Quarter for Celgene Corporation (NASDAQ:CELG)

Receive News & Stock Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related stocks with our FREE daily email newsletter.